| Identification | Back Directory | [Name]
MK-3697 | [CAS]
1224846-01-8 | [Synonyms]
CS-673
MK-3607
MK-3697
Mk3697/Mk-3697
MK-3697 , CID 46190695
MK-3697; MK3697; MK 3697.
N-[(5,6-Dimethoxy-2-pyridinyl)methyl]-5'-methyl-5-(2-thiazolyl)-[2,3'-bipyridine]-4-carboxamide
N-((5,6-diMethoxypyridin-2-yl)Methyl)-5'-Methyl-5-(thiazol-2-yl)-[2,3'-bipyridine]-4-carboxaMide
[2,3'-Bipyridine]-4-carboxamide, N-[(5,6-dimethoxy-2-pyridinyl)methyl]-5'-methyl-5-(2-thiazolyl)-
N-[(5,6-diMethoxypyridin-2-yl)Methyl]-5'-Methyl-5-(1,3-thiazol-2-yl)-2,3'-bipyridine-4-carboxaMide
N-[(5,6-DIMETHOXYPYRIDIN-2-YL)METHYL]-2-(5-METHYLPYRIDIN-3-YL)-5-(1,3-THIAZOL-2-YL)PYRIDINE-4-CARBOXAMIDE | [Molecular Formula]
C23H21N5O3S | [MDL Number]
MFCD22572350 | [MOL File]
1224846-01-8.mol | [Molecular Weight]
447.51 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10 mg/ml; DMF:PBS (pH 7.2) (1:2): 0.33 mg/ml; DMSO: 1 mg/ml | [form ]
A solid | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
MK-3697 is an isonicotinamide small molecule, acting as a potent and selective Orexin 2 receptor antagonist with Ki = 0.95 nM.
IC50 value: 0.95 nM(Ki)
Target: Orexin 2 receptor antagonist
MK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists (2-SORAs) that possess acceptable profiles for clinical development. Herein we report additional SAR studies within the “triaryl” amide 2-SORA series focused on improvements in compound stability in acidic media and time-dependent inhibition of CYP3A4. MK-3697 has improved stability and TDI profiles as well as excellent sleep efficacy across species. | [References]
[1] Anthony J. Roecker, et al. Discovery of MK-3697: A Selective Orexin 2 Receptor Antagonist (2-SORA) for the Treatment of Insomnia. Bioorganic & Medicinal Chemistry Letters Available online 26 August 2014 |
|
|